Approval · Notice of Compliance 28630 · 2022
NAPROXEN: Notice of Compliance 28630
Issued July 21, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28630
- Date
- July 21, 2022
- Company
- Pharmascience Inc.Montreal, Quebec, Canada
- Product type
- Nonprescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Addition of private retailer label. Revisions to the product labels
- Canadian reference product
- ALEVE (Bayer Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NAPROXEN | Not yet assigned | — |
Medicinal ingredients
- NAPROXEN SODIUM 220 MG per TAB